NCT02135042 2026-03-18Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNANRG OncologyPhase 2/3 Active not recruiting685 enrolled
NCT05063552 2026-03-18Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersNational Cancer Institute (NCI)Phase 2/3 Active not recruiting430 enrolled